Please assess the completion status of the following clinical trial:

Trial Title: The Combiotic-Study

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: None
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Healthy term infants~* Female or male gender~* Gestational age between 37 and 41 weeks completed (= 41 weeks + 6 days)~* Age at time of V1 visit : 4 +/- 7 days~* Birth weight between 2500 ans 4200g, with regular weight gain (≥ 150g / week)~* Two legal representatives (parent(s) / guardian(s)) who are capable of and willing to comply with the protocol and have signed the informed consent in accordance with legal requirements.~* at least one of the legal representatives is affiliated to with a social security scheme.~Additionnaly , criteria of inclusion in one of the formula-fed groups or in the breast-fed group, respectively, are the following:~* To be included in one of the formula arm, infants will have to be exclusively formula-fed (no breast milk meal) at the time of V1 visit (randomization).~or~* To be included in the breastfeeding arm, infants will have to be exclusively breast-fed (no more than one formula meal per day) at V1 visit (randomization) and its mother will have to be willing to pursue exclusive breastfeeding at least until the infant will be 4-month old.~Exclusion Criteria:~* Intensive care during at least the first 14 days of life~* Neonatal health problems, such as: respiratory distress, asphyxia, hypoglycemia, sepsis, NEC (necrotizing enterocolitis),...~* Clinical evidence of chronic illness or gastrointestinal disorders such as : GER (Gastrooesophageal Reflux), gastroenteritis,...~* Known metabolic disorders, such as diabetes, lactose intolerance,....~* Known immune deficiency~* Subjects recommended to receive formula with hydrolized protein (e.g. children with allergy risk)~* Subject under oral antibiotic treatment at V1 visit~* Participation in another biomedical study~* Whose legal representatives have psychological or linguistic incapability to sign the informed consent form~* Reasons to presume that parents are unable to meet the study plan requirements (e.g. impossibility to contact study representatives in case of emergency, drug addiction etc)

- Gender: ALL
- Minimum Age: 3 Weeks
- Maximum Age: 5 Weeks
- Healthy Volunteers: t

Study Arms:
- Synbiotic formula (Type: EXPERIMENTAL): Synbiotic formula : standard formula enriched with a prebiotic fiber and a probiotic strain~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water, according to the Dose and Drinking Amount table.~Route : oral, ad libitum~Duration of product intake:~* Synbiotic IF : 5 months of consumption (from the inclusion until 6 months completed of age)~* Synbiotic FoF: 6 months of consumption (from 6 to 12 months of age)
- Control formula (Type: PLACEBO_COMPARATOR): Control formula : standard formula without pre and probiotic~Dose : variable number of powder scoops, adapted to the infant's age and weight, and addition of the defined amount of water according to the Dose and Drinking Amount table.~Route: oral, ad libitum~Duration of product intake:~* Control IF : 5 months of consumption (from the inclusion until 6 months completed of age)~* Control FoF : 6 months of consumption (from 6 to 12 months of age)
- Breast-fed group (Type: NO_INTERVENTION): - Breast milk as exclusive feeding (no more than one formula meal per day), from birth until at least 4 months of age. Then, when the mother decides to stop breastfeeding, the infants can consume any formula on parent's choice respecting forbidden products list.~Dose:~* Breast milk : on demand~Route : oral, ad libitum~Duration of product intake:~* Breast milk : at least 4 month (from birth until at least 4 months of age)

Based on this trial design, predict the completion outcome and termination type (if applicable).